SCHEMBL2333808

SCHEMBL2333808

O=C(O)c1cc(F)cnc1Oc1cc(Cl)ccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 9/20 0.49
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.42
RHEB Q15382 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
UGCG Q16739 1/20 0.42
PTGER4 P35408 2/20 0.42
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SCN9A Q15858 2/20 0.41
CCR2 P41597 1/20 0.41
CCR4 P51679 1/20 0.41
CCR5 P51681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2781306 0.91 MRGPRX4 (0.50) ALDH1A1MRGPRX4UGCGTSHRCASP1
SCHEMBL2337128 0.89 GPBAR1 (0.46) GPBAR1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2779885 0.83 TDP1 (0.55) CYP1A2CYP2C9UGCGPTGER4TSHR
SCHEMBL6062735 0.81 PTGER4 (0.48) CYP1A2PTGER4SCN9ACCR2
SCHEMBL2333648 0.80 PTGER4 (0.51) ALDH1A1CYP1A2CYP2C9CYP2C19PTGER4
SCHEMBL2333146 0.80 PTGER4 (0.47) CYP2C9PTGER4TSHRSMN1; SMN2SCN9A
SCHEMBL3142832 0.80 GPBAR1 (0.56) GPBAR1ALDH1A1TP53CYP3A4UGCG
SCHEMBL2216478 0.80 GPBAR1 (0.69) GPBAR1ALDH1A1TP53CYP1A2CYP3A4
SCHEMBL2330578 0.79 ALDH1A1 (0.51) ALDH1A1TP53MRGPRX4RHEBCYP1A2
SCHEMBL2335696 0.78 GPBAR1 (0.60) GPBAR1ALDH1A1TP53MRGPRX4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309734-B2 Substituted pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2356094-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. Hoffmann-La Roche AG (CH) 2011-08-17 EP disclosed
WO-2010049302-A1 NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105906-A1 NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES GPBAR1, GPR119, GLP1R GPBAR1 1/4885ALDH1A1 341/4885TP53 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.